Aurobindo Pharma Limited has informed the Exchange about expanding existing CMO operations with Merck Sharpe & Dohme Singapore Trading Pte. Ltd by TheraNym Biologics Private Limited, a subsidiary of the Company

Export Order Hard CurrencyBusiness Updates View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.7%1-day move

₹1375.00

prior close

₹1389.90

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.5-1.0-1.0-1.1+0.7-0.7+1.0+3.6+4.7+3.3+8.0+9.1+2.0+12.7

Up moveDown movePending

AI summary

Aurobindo Pharma's subsidiary TheraNym Biologics has signed an additional product schedule with Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD) to expand their existing contract manufacturing relationship. TheraNym will build a greenfield mammalian Drug Substance manufacturing facility (Unit 2) with 60,000 litres of bioreactor capacity for producing biologics. The investment is estimated at USD 150-175 million. This expands on the initial CMO arrangement disclosed in May 2024. TheraNym will construct the facility, manufacture products, and supply them to MSD.

Likely market impact

This is a significant positive development for Aurobindo Pharma as it deepens their partnership with global pharma major MSD and signals entry into mammalian cell culture biologics manufacturing, a high-growth segment. The substantial capital investment indicates long-term revenue visibility.